Active connections
Name | Gender | Age | Linked companies | Collaboration |
---|---|---|---|---|
Patrick W. Phelps | M | - |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | 16 years |
Allan J. Pantuck | M | - |
Athos Therapeutics, Inc.
Athos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then. | 5 years |
Dimitrios Iliopoulos | M | - |
Athos Therapeutics, Inc.
Athos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then. | 5 years |
Michael Jung | M | - |
Athos Therapeutics, Inc.
Athos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then. | 5 years |
Carl McKinzie | M | 84 |
Athos Therapeutics, Inc.
Athos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then.
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | - |
Michael E. Phelps | M | - |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | 16 years |
Philipp G. Czernin | M | - |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | - |
Melissa Moore | M | - |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | - |
K. Judson | M | 62 |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | 14 years |
Howard Maron | M | - |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | - |
Ken Herrmann | M | 47 |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | - |
Stan Berman | M | - |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | - |
Kanwar Rameshwar Singh Jamwal | M | - |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | - |
Eddie Park | M | - |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | 11 years |
Ajit Singh | M | 60 |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | 13 years |
Nam T. Vu | M | - |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | 15 years |
Bob Balch | M | - |
Sofie Biosciences, Inc.
Sofie Biosciences, Inc. Medical SpecialtiesHealth Technology Sofie Biosciences, Inc. operates as a diagnostics company that provides molecular imaging probes and devices to help scientists and physicians investigate the biology of disease. It combines the discovery and development of new PET imaging probes with innovative imaging systems and chemistry platforms to provide researchers and physicians with tools to better understand the biology of disease. The company was founded by Owen N. Witte, Michael E. Phelps, Jim Heath, Johannes Czernin, and Caius Radu in 2008 and is headquartered in Culver City, CA. | - |
Abraham Verghese | M | - |
Athos Therapeutics, Inc.
Athos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Athos Therapeutics, Inc. is a biotech company based in Torrance, CA. Athos Therapeutics develops small molecule therapeutics for immune-mediated diseases using artificial intelligence-generated innovative chemistry and computational platforms. The private company identifies novel drug targets by integrating clinical and molecular datasets into the biological network of a disease and matches them to its small molecule computational chemistry platform. Ath-63, the company's lead drug compound, is moving into a phase I human clinical trial for patients with inflammatory bowel disease in Q1 2022 at the Cleveland Clinic. Other pipeline programs include drugs for lupus and various types of cancers. The company was founded in 2019 by Michael Jung, Allan J. Pantuck, and Dimitrios Iliopoulos, who has been the CEO since then. | 2 years |
Connections Chart
Multi-company connection
Statistics
Country | Connections | % of total |
---|---|---|
United States | 18 | 100.00% |
Age of Connections
Active
Past
Male
Female
Members of the board
Executives
Origin of connections
- Stock Market
- Insiders
- Joel Cohen
- Personal Network